Pfizer (PFE) Net Worth & Market Cap: Interactive Chart & Insights
How can a pharmaceutical giant's financial trajectory be understood in the volatile landscape of global markets? The story of Pfizer, a titan in the biopharmaceutical industry, unfolds through its fluctuating market capitalization, offering a compelling narrative of innovation, market dynamics, and leadership.
The value of a company, often simplified for understanding, is intrinsically linked to its market capitalization. This figure, the product of the current stock price and the total number of outstanding shares, serves as a vital benchmark. Understanding this allows for a more comprehensive grasp of a company's financial health and its standing in the industry. As of April 22, 2025, Pfizer's net worth stood at $125.57 billion, a figure that fluctuates with market forces. Just a few days later, on April 25, 2025, the market cap had shifted, registering at $129.99 billion. This dynamic nature highlights the constant interplay of factors influencing valuation.
The most recent data points showcase the evolution of Pfizer's market capitalization. On Friday, March 21, 2025, the market cap for Pfizer (PFE) was reported at $147.94 billion. A recent increase of 0.83% over the past 30 days suggests a period of growth. However, the past year paints a different picture, with a 5.55% decrease in market cap. This showcases the volatile nature of the market and the sensitivity of a companys value to various internal and external influences. The company is currently ranked as the 105th largest in the world, a significant position that highlights its influence in the global economy.
Focusing on the recent financial trends, the market cap in April 2025 was approximately $129.98 billion USD. Based on data analysis, Pfizer ranks as the world's 121st most valuable company by market capitalization. The company's market cap or net worth currently sits at $129.99 billion, and the enterprise value is noted as $176.93 billion. The forthcoming earnings date is set for Tuesday, April 29, 2025, preceding the market's opening. These details provide insights into the company's financial health and future prospects.
Pfizer's operational structure includes 5.67 billion shares outstanding. The trailing Price-to-Earnings (P/E) ratio stands at 16.26, with a forward P/E ratio of 7.78. Further estimates place the net worth of Pfizer at around $247 billion. The company is described as an American global ergonomics and pharmaceutical entity, with a net worth of $210 billion. With its headquarters located in Manhattan, New York City, Pfizer is acknowledged as a leading biopharmaceutical business.
The company's 2025 sales outlook remains steady, targeting around $61 billion. This indicates management's expectations and strategic vision for the year. Albert Bourla, the Chairman and CEO of Pfizer Inc., holds approximately 81,812 shares of Pfizer Inc. (PFE) stock, estimated to be worth over $2 million. Further insights are available in Albert Bourla's holdings summary. The current market capitalization of Pfizer (pharmaceuticals) is $130 billion. This gives a snapshot of the company's present valuation in the market.
| Attribute | Details |
|---|---|
| Name | Albert Bourla |
| Title | Chairman and CEO of Pfizer Inc. |
| Estimated Net Worth | $14.5 million (based on reported shares in Pfizer Inc.) |
| CIC | 0001595703 |
| Leadership | Instrumental in establishing Pfizer as a leading name in the pharmaceutical industry. |
| Shareholding | Owns approximately 81,812 shares of Pfizer Inc. (PFE) stock, valued over $2 million. |
| Notable Affiliations | Involved in the management of SpringWorks Therapeutics Inc. through Pfizer Inc.'s 10% ownership and shareholding of approximately 4,593,847 shares of SpringWorks Therapeutics Inc. (SWTX) stock, valued over $229 million. |
| Reference | Pfizer Official Website |
Pfizer's financial data provides various snapshots of its performance. As of February 14, 2025, the company's market cap or net worth was reported at CAD 204.98 billion. The market cap experienced a 0.20% rise over a year. Additionally, on February 12, 2025, the market cap or net worth was noted as 2.96 trillion, with an increase of 11.18% over the year. Data from people ai estimates Pfizer's salary income and net worth. An analysis of Pfizers net worth in February 2025 in US dollars offers a comprehensive view.
The company's operational scope encompasses the discovery, development, manufacturing, marketing, sale, and distribution of biopharmaceutical products globally. The company's business activities demonstrate its engagement in the field. Pfizer's comprehensive activities are key to its continued industry relevance.
The company is involved in worldwide markets with diverse products and sales strategies. A critical aspect of its operations includes a comprehensive product strategy, and constant global efforts to refine their market strategies.
In a letter to shareholders, it was mentioned that 2023, while marked by certain challenges, also saw significant achievements. These achievements set the stage for further progress in 2024 and beyond, as Pfizer celebrates 175 years of pioneering innovations. It is important to highlight the favorable impact of a tax benefit of approximately nine billion U.S. dollars on the high net income in 2017. Pfizers net income from 2006 to 2024 (in million U.S. dollars) offers a crucial context for understanding the company's financial health. This information gives us a valuable financial perspective on the company's operations.
As of March 2025, the market capitalization of Pfizer (PFE) was noted as $147.94 billion. Its market cap increased by 0.83% over the past 30 days. Moreover, over the previous 12 months, Pfizer's market cap decreased by 5.55%. Pfizer Inc. is a significant player on the global stage.
